Synthesis and characterization of new Piperazine-Dithiocarbamate compounds as potent MAO-A inhibitors
European Journal of Life Sciences · 2022
DOI: 10.55971/ejls.1089254 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Life Sciences, 2022. Verfasst von Derya Osmaniye und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Monoamine oxidase (MAO) enzymes have an important place in neurodegenerative diseases. While MAO-A inhibitors are used in depression; MAO-B enzyme has an important place in Parkinson's disease. Within the scope of this study, 7 new piperazine-dithiocarbamate derivative compounds were synthesized. Structure determinations of the compounds were performed using 1H-NMR, 13C-NMR and HRMS spectroscopic methods. The MAO inhibitory activities of the compounds were determined by in vitro fluorometric methods. According to the obtained results, compound 2d with IC50=0.108±0.004 µM; compound 2e exhibited inhibitory activity with an IC50=0.074±0.003 µM.
Zitieren
APA
Osmaniye, D., Saglik, B. N., Levent, S., Özkay, Y., & Kaplancıklı, Z. A. (2022). Synthesis and characterization of new Piperazine-Dithiocarbamate compounds as potent MAO-A inhibitors. European Journal of Life Sciences. https://doi.org/10.55971/ejls.1089254
Vancouver
Osmaniye D, Saglik BN, Levent S, Özkay Y, Kaplancıklı ZA. Synthesis and characterization of new Piperazine-Dithiocarbamate compounds as potent MAO-A inhibitors. European Journal of Life Sciences. 2022. doi:10.55971/ejls.1089254
BibTeX
@article{Osmaniye2022,
author = {Osmaniye, Derya and Saglik, Begüm Nurpelin and Levent, Serkan and Özkay, Yusuf and Kaplancıklı, Zafer Asım},
title = {Synthesis and characterization of new Piperazine-Dithiocarbamate compounds as potent MAO-A inhibitors},
journal = {European Journal of Life Sciences},
year = {2022},
doi = {10.55971/ejls.1089254}
}
EUVIMED